Linagliptin

Evidensnivå: L5

Förutsagda indikationer: 0 st

Innehållsförteckning

Linagliptin
Linagliptin: Type 2 Diabetes Drug — No Repurposing Candidates Identified

## Apotekarens bedömningsrapport

Linagliptin: Type 2 Diabetes Drug — No Repurposing Candidates Identified

One-Sentence Summary

Linagliptin (DB08882) is a well-established DPP-4 inhibitor originally approved for the management of Type 2 Diabetes Mellitus. However, the TxGNN model returned no predicted new indications for this drug in the current evidence pack. Evaluation cannot proceed to indication-level analysis until the prediction pipeline is re-run and evidence data is populated.

Quick Overview

Item	Content
Original Indication	Type 2 Diabetes Mellitus (DPP-4 inhibitor class)
Predicted New Indication	None identified (predicted_indications: empty)
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only; no output returned
Sweden/Taiwan Market Status	Not marketed (0 authorizations on record)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction is available from the current Evidence Pack. The predicted_indications array is empty, which means the TxGNN model either did not produce a ranked output for Linagliptin, or the pipeline did not complete successfully for this candidate.

Mechanism of action data is also marked as a data gap. Based on class-level knowledge, Linagliptin is a selective, competitive inhibitor of dipeptidyl peptidase-4 (DPP-4), which prolongs the action of incretin hormones (GLP-1 and GIP) to stimulate glucose-dependent insulin secretion. Whether this mechanism could translate to other indications (e.g., non-alcoholic fatty liver disease, heart failure, renal protection) is a plausible hypothesis explored in published literature — but no model-based prediction is currently available to evaluate.

Without a prediction from TxGNN, this report cannot perform indication-level reasoning, clinical trial mapping, or literature linkage.

Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication to map evidence against.

Literature Evidence

Currently no related literature available — no predicted indication to anchor a literature review.

Sweden Market Information

No authorizations on record in the current dataset. The query against TFDA (query ID: 1) returned 0 results, and no license records are present in taiwan_regulatory.licenses.

Note: Linagliptin is commercially available in multiple markets under brand names such as Tradjenta (Boehringer Ingelheim / Eli Lilly). The absence of records here may reflect a data gap in the current pipeline run rather than a genuine market absence. Cross-verification with MPA (Swedish Medical Products Agency) and TFDA databases is recommended.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields (key warnings, contraindications, drug interactions) returned as data gaps or empty in this evidence pack. The DDI query returned not_found with 0 interactions recorded.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction pipeline returned no candidate indications for Linagliptin, making it impossible to evaluate repurposing feasibility. No scoring, evidence triangulation, or safety mapping can be completed at this stage.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline for DB08882 and verify that predicted_indications is populated with at least one scored candidate
Retrieve MOA data from DrugBank API (data gap DG002) to enable mechanism-to-indication reasoning
Retrieve TFDA package insert warnings and contraindications (data gap DG001, currently blocking S1 safety screening)
Verify market status against MPA (Sweden) and TFDA (Taiwan) directly — the current record of 0 authorizations is inconsistent with known global availability
Re-run DDI query using an alternative source (e.g., DrugBank interactions endpoint or Drugs@FDA) since the current query returned not_found
Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.